Effect or porcine collagen graft for increasing keratinised tissue

  • Research type

    Research Study

  • Full title

    Effect or porcine collagen graft for increasing the width of keratinised tissues on peri-implant mucositis: A clinical and molecular study.

  • IRAS ID

    219043

  • Contact name

    Charles Maran

  • Contact email

    cmaran@exseed.ed.ac.uk

  • Sponsor organisation

    NHS Lothian

  • ISRCTN Number

    ISRCTN83600326

  • Duration of Study in the UK

    1 years, 0 months, 1 days

  • Research summary

    Peri-implant mucositis is an inflammatory condition whereby the tissues surrounding dental implants become inflamed, swollen and bleed. The primary causal agent is dental plaque but can be multifactorial.

    The ability of patients to conduct adequate oral hygiene is paramount to preventing and treating peri-impant mucositis. If left untreated, it is possible that the condition may progress to peri-implantits with subsequent bone loss around the implant.

    Keratinised mucosa is more resilient than oral mucosa and provides a less mobile cuff of tissue around dental implants. It is less uncomfortable to clean around and may enable patients to conduct more effective plaque removal practices.

    This split mouth prospective clinical trial aims to improve the thickness of keratinised mucosa around dental implants with peri-implant mucositis via the use of a porcine collagen graft. Post healing, this increased thickness of resilient tissue should enable the patients to perform better oral hygiene and facilitate resolution of the peri-implant mucositis.

    The patients will be recruited from those who already attend the restorative department of the Edinburgh Dental Institute and are seen on review following placement of mandibular dental implants and provision of an implant retained over denture

    Patients included in the study will have undergone a course of non-surgical treatment and supportive therapy to identify patients where these measures have not been successful in resolving the peri-implant mucositis

    Geistlich ( a Swiss Biomaterials company ) will fund the project .

  • REC name

    East of Scotland Research Ethics Service REC 2

  • REC reference

    18/ES/0005

  • Date of REC Opinion

    22 May 2018

  • REC opinion

    Further Information Favourable Opinion